Machine Learning

Identity verification firm SentiLink hires Kathleen Waid as CRO, signaling an aggressive growth strategy amid the rise of AI-powered financial crime.

With its new EviChat AI, Woodway Assurance’s EviData 2.0 automates complex data privacy risk assessments, promising to unlock faster innovation.

RAD Intel's new platform offers enterprise-grade audience intelligence to smaller firms, challenging the high-cost tools used by market giants.

After gaining FDA alignment, INmune Bio is advancing its inflammation-targeting drug, XPro1595, offering a novel and potentially safer approach for patients.

The London Stock Exchange's new private market is live, promising a new era of liquidity for high-growth firms and reshaping the path from startup to exit.

Led by decorated medallists Mollie Jepsen and Alexis Guimond, Canada's eight-skier Para alpine team blends veteran grit with rising stars for Italy.

Soar Autism Center launches a free, 40-hour RBT course focused on the play-based ESDM model, tackling workforce shortages and raising care standards.

Solana Company is building a massive infrastructure in Asia, but can this bold, high-risk play conquer the complex regulatory landscape and win the race?

Acquiring Complete Genomics, Swiss Rockets unveils its CoolMPS 600, a bid to democratize long-read sequencing with breakthrough cost and accuracy.

A new self-serve platform offers on-demand NVIDIA and AMD systems locally, providing an alternative to cloud costs and lock-in for AI and VFX industries.

A Korean firm says it can cure 34 diseases using cells from cloned embryos, walking a fine line between a medical breakthrough and a bioethical taboo.

ZEISS launches Collaborative Care, a cloud-based solution to connect optometrists and ophthalmologists, streamlining referrals and data sharing for better care.

The AI-native platform is the only vendor named a Leader in both utilities EAM and FSM reports, challenging legacy systems with a unified approach.

A new summit reveals the high-stakes, collaborative effort to build the open standards that will move AI agents from futuristic demos to enterprise reality.

Most hospitals have static defenses ill-equipped for modern threats. A new, free framework offers a clinically-informed path to a dynamic Zero Trust posture.

Recursion, HighRes, and NVIDIA are pioneering automated drug discovery. Inside the 'Physical AI' revolution poised to radically accelerate the hunt for new cures.

With its stock under pressure, Geron will face investors to defend its RYTELO sales strategy and address delays in its pivotal myelofibrosis trial.

New federal initiatives are fast-tracking deep brain stimulation research, a move championed by Nexalin Technology that could revolutionize care for veterans.

Amid financial headwinds, CISO Global appoints a new EVP to accelerate AI innovation, enhance operational efficiency, and gain a competitive edge.

BioVie faces a pivotal moment, touting breakthrough drugs for Alzheimer's and cirrhosis while navigating clinical setbacks and financial pressures.